Document is current

Article History

Received: 24 January 2022

Accepted: 4 March 2022

First Online: 28 March 2022

Declarations

:

: The trial was approved by the Ethics Committee of Charité – Universitätsmedizin Berlin (REC reference EA2/033/19) on 13 March 2019 prior to the start of recruitment. Any substantial amendments to the protocol or to the consent materials must also be approved by the Ethics Committee of Charité – Universitätsmedizin Berlin before implementation.All participants (means participants or participant or parent/legal guardian according to age) give their full consent before they or their children are enrolled into the trial. The informed consent form must be revised whenever important new safety information is available, whenever the protocol is amended leading to changes in study procedures relevant for the patient, and/or whenever any new information becomes available that may affect participation in the trial.

: Not applicable.

: VT received speaker’s fees from Nutricia/Danone. Kirsten Beyer reports grants/research supports from Aimmune, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, and honoraria or consultation fees from Aimmune, Bencard, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma, Mylan/Meda, Nestle, Novartis, and ThermoFisher outside of the submitted work. Margitta Worm declares the receipt of honoraria or consultation fees by the following companies: ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co. KG, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG., AbbVie Deutschland GmbH & Co. KG, and Lilly Deutschland GmbH. All other authors report that they have no competing interests.